Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Viveon Health Acquisition Corp. Announces Closing of $175 Million Initial Public Offering
-
Viveon Health Acquisition Corp. Announces Closing of $175 Million Initial Public Offering
-
Ventoux CCM Acquisition Corp. (VTAQ) Prices 15M Unit IPO at $10/Unit
-
Ventoux CCM Acquisition Corp. Announces Pricing of $150 Million Initial Public Offering
-
Form 3 Ventoux CCM Acquisition For: Dec 23 Filed by: Chardan International Investments, LLC
-
Viveon Health Acquisition Corp. (VHAQ) Prices 17.5M Unit IPO at $10/Unit
-
Viveon Health Acquisition Corp. Announces Pricing of $175 Million Initial Public Offering
-
Viveon Health Acquisition Corp. Announces Pricing of $175 Million Initial Public Offering
-
MeiraGTx Holdings plc (MGTX) PT Raised to 'Street High' $55 at Chardan Capital Markets
-
Globis Acquisition Corp. Announces Closing of $115 Million Initial Public Offering, which Includes Full Exercise of the Underwriters' Over-Allotment Option
-
Globis Acquisition Corp. Announces Pricing of $100 Million Initial Public Offering
-
Globis Acquisition Corp. Announces Pricing of $100 Million Initial Public Offering
-
CRISPR Therapeutics (CRSP) PT Raised to $166 at Chardan Capital Markets
-
Meten EdtechX Announces Temporary Offer Allowing Warrants to be Exercised at a Reduced Price
-
UPDATE: Chardan Capital Markets Downgrades Mesoblast Limited (MESO) to Sell
-
3 Penny Stocks To Buy According To Analysts; 146%-579% Price Targets
-
MeiraGTx Holdings plc (MGTX) Prices 5M Share Offering at $12.85/Sh
-
MeiraGTx (MGTX) Announces Pricing of Public Offering of 5M Ordinary Shares at $12.85/sh
-
MeiraGTx Announces Pricing of Public Offering of Ordinary Shares
-
MeiraGTx Announces Pricing of Public Offering of Ordinary Shares
-
MeiraGTx Holdings plc (MGTX) Announces Proposed 5M Share Public Offering of Ordinary Shares
-
MeiraGTx Announces Proposed Public Offering of Ordinary Shares
-
MeiraGTx Announces Proposed Public Offering of Ordinary Shares
-
Orisun Acquisition Corp. and Ucommune Group Holdings Limited Announce Closing of Business Combination
-
Chardan Acts as Lead Left Book-Runner in Natural Order Acquisition Corp.'s Oversubscribed $230 Million IPO
-
Natural Order Acquisition Corp. Announces Closing of $230 Million Initial Public Offering, which Includes Full Exercise of the Underwriters' Over-Allotment Option
-
Immunovant (IMVT) PT Raised to $60 at Chardan Capital Markets
-
Natural Order Acquisition Corp. (NOAC) Prices 20M Unit IPO at $10/Unit
-
Natural Order Acquisition Corp. Announces Pricing of $200 Million Initial Public Offering
-
Form 10-Q Chardan Healthcare Acqui For: Sep 30
-
Forte Biosciences Announces Closing of $46.0 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Mallard Acquisition Corp. Announces Closing of $110 Million Initial Public Offering
-
Forte Biosciences (FBRX) Announces Pricing of $40 Million Public Offering of Common Stock at $28.50/sh
-
Forte Biosciences Announces Pricing of $40.0 Million Public Offering of Common Stock
-
Forte Biosciences (FBRX) Announces Proposed Public Offering of Common Stock
-
Forte Biosciences Announces Proposed Public Offering of Common Stock
-
Mallard Acquisition Corp. Announces Pricing of $110 Million Initial Public Offering
-
Chardan Capital Markets Starts Axcella Health Inc. (AXLA) at Buy, $16 PT; 'Simplified Approach to Improving Metabolic Health'
-
UPDATE: Chardan Capital Markets Starts Immunome Inc. (IMNM) at Buy, Bullish on Antibody Discovery Platform
-
Longevity Acquisition Corporation Announces Signing of Definitive Merger Agreement
-
Gensight Biologics Successfully Raises €25 Million in an Oversubscribed Private Placement With Us and European Institutional Investors
-
Chardan Capital Markets Starts Taysha Gene Therapies (TSHA) at Buy
-
Hudson Capital Inc. Enters into Definitive Merger Agreement with FreightHub, Inc., a North American Digital Transportation Logistics Platform Company with a Focus on US-Mexico Cross-Border Shipping
-
Immunome Announces Exercise in Full and Closing of Over-Allotment Option in Initial Public Offering
-
Iovanace Biotherapeutics (IOVA) PT Lowered to $50 at Chardan Capital Markets on Delay
-
Oncorus to Present at Chardan 4th Annual Genetic Medicines Conference
-
Oncorus to Present at Chardan 4th Annual Genetic Medicines Conference
-
LogicBio Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
LogicBio Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
CARISMA Therapeutics to Participate in Upcoming Investor Conferences

